Tohumcu Ege, Kaitsas Francesco, Bricca Ludovica, Ruggeri Alessandro, Gasbarrini Antonio, Cammarota Giovanni, Ianiro Gianluca
Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy.
Department of Medical and Surgical Sciences, UOC Gastroenterologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
Antibiotics (Basel). 2024 Jun 24;13(7):584. doi: 10.3390/antibiotics13070584.
is a type of Gram-negative bacteria belonging to the Proteobacteria phylum which is known to cause gastrointestinal disorders such as gastritis and gastric ulcers. Its treatment is based on current eradication regimens, which are composed of combinations of antibiotics such as clarithromycin, metronidazole, levofloxacin and amoxicillin, often combined with a proton pump inhibitor (PPI). With the development of sequencing technologies, it has been demonstrated that not only does the colonization of the gastric and gut environment by cause microbial changes, but also the treatment regimens used for its eradication have a significant altering effect on both the gastric and gut microbiota. Here, we review current knowledge on microbiota modulations of current therapies in both environments. We also summarize future perspectives regarding infection, the integration of probiotics into therapy and what challenges are being faced on a global basis when we talk about eradication.
是一种属于变形菌门的革兰氏阴性菌，已知会引起胃肠道疾病，如胃炎和胃溃疡。其治疗基于当前的根除方案，该方案由克拉霉素、甲硝唑、左氧氟沙星和阿莫西林等抗生素组合而成，通常还会与质子泵抑制剂（PPI）联合使用。随着测序技术的发展，已证明不仅该菌在胃和肠道环境中的定殖会引起微生物变化，而且用于根除它的治疗方案对胃和肠道微生物群也有显著的改变作用。在此，我们综述了当前关于这两种环境中当前疗法对微生物群调节的认识。我们还总结了关于该菌感染的未来展望、益生菌在治疗中的整合以及在全球范围内谈论根除时所面临的挑战。
